Rapid Decreases in Blood Pressure from Antihypertensive Treatment were Associated with Increased Cancer Mortality in the Systolic Hypertension in the Elderly Program

Swerdel, Joel N.; Janević, Teresa; Cabrera, Javier; Cosgrove, Nora M.; Sedjro, Jeanine E.; Pressel, Sara L.; Davis, Barry R.; Kostis, John B.

doi:10.1158/1055-9965.epi-14-0085

Cited by 5 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Essa escala tem sido utilizada em vários setores, mas principalmente na unidade de terapia intensiva (UTI), tanto na prática assistencial como em pesquisas relacionadas a prevenção das LPP. SWERDEL et al, 2014).…”

Section: Resultsunclassified

Anais do Iº Congresso Internacional de Saúde Pública e Coletiva no SUS

Capelario¹,

Silva²,

Silveira³

et al. 2023

View full text Add to dashboard Cite

pelo Instituto Pesquisa & Ciência (CNPJ: 25.255.510/0001-30), procura a promoção da pesquisa científica, com base nas diversas áreas do conhecimento e com a presença multidisciplinar de pesquisadores, estudantes e profissionais, de modo a contribuir com a troca de experiências e aprendizado científico.Conteúdo, revisão gramatical, erros de linguagem, correção e confiabilidade dos estudos contidos nesse e-book, são de responsabilidade exclusiva dos autores, que não representam a posição oficial do Instituto Pesquisa & Ciência. O compartilhamento e download da obra é permitido, desde que os créditos aos autores sejam atribuídos.Feita por pares, a avaliação cega foi realizada pelos membros do Conselho Editorial, descritos nessa edição, todos os estudos foram avaliados e aprovados para publicação, seguindo critérios de neutralidade e imparcialidade.

show abstract

Section: Resultsunclassified

Anais do Iº Congresso Internacional de Saúde Pública e Coletiva no SUS

Capelario¹,

Silva²,

Silveira³

et al. 2023

View full text Add to dashboard Cite

show abstract

“…(any) cancer-related death following effective control of hypertension with antihypertensives. 76,77 Furthermore, discovery of how hypertension affects survival may identify patients who will most benefit from bevacizumab treatment, or pathways that could be targeted in combination with bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

“…This is an important distinction, because if hypertension improves treatment outcome, this may alter how hypertension is managed in patients treated with bevacizumab, particularly given the evidence for increased microvascular density and heightened risk of (any) cancer-related death following effective control of hypertension with antihypertensives. 76 , 77 Furthermore, discovery of how hypertension affects survival may identify patients who will most benefit from bevacizumab treatment, or pathways that could be targeted in combination with bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab-Induced Hypertension in Glioblastoma Patients and Its Potential as a Modulator of Treatment Response

et al. 2023

View full text Add to dashboard Cite

Glioblastoma invasion is the primary mechanism responsible for its dismal prognosis and is the direct result of interactions between glioblastoma cells and the tumor vasculature. The dysregulated microvasculature in glioblastoma tumors and vessels co-opted from surrounding brain tissue support rapid tumor growth and are utilized as pathways for invasive cancer cells. Attempts to target the glioblastoma vasculature with antiangiogenic agents (eg, bevacizumab) have nonetheless shown limited and inconsistent efficacy, and the underlying causes of such heterogeneous responses remain unknown. Several studies have identified that patients with glioblastoma who develop hypertension following treatment with bevacizumab show significant improvement in overall survival compared with normotensive nonresponders. Here we review these findings and discuss the potential of hypertension as a biomarker for glioblastoma treatment response in individual patients and the role of hypertension as a modulator of interactions between tumor cells and cells in the perivascular niche. We suggest that a better understanding of the actions of bevacizumab and hypertension at the cellular level will contribute to developing more effective personalized therapies that address glioblastoma tumor cell invasion.

show abstract

“…Goldstein and Mascitelli (1) for their careful reading of our article (2). In our introduction, we identified prior reports of the association of antihypertensive treatment with cancer and found the results from previous work to be equivocal.…”

mentioning

confidence: 99%

Cancer Death and Antihypertensive Drug Treatment—Response

Swerdel

Kostis

2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

We wish to thank Drs. Goldstein and Mascitelli (1) for their careful reading of our article (2). In our introduction, we identified prior reports of the association of antihypertensive treatment with cancer and found the results from previous work to be equivocal.We are aware of the findings of PROSPER in which new cancer diagnoses were more frequent on pravastatin than on placebo (1.25, 1.04-1.51, P ¼ 0.020). In the discussion of the PROSPER article, Shepherd and colleagues discuss the potential of carcinogenicity with cholesterol-lowering drugs (3). In the Cholesterol Treatment Trialists' Collaborators 2005 meta-analysis of 90,056 participants, the rate of cancer was the same in the statin and control groups (1.00; 95% confidence interval, 0.95-1.06; P ¼ 0.9) (4). However, in a later meta-analysis that examined the interaction between statin use and aging (n ¼ 42,902), Bonovas and colleagues found that age significantly modified the effect of statins on cancer risk (5). It is possible that age is an effect modifier in the association between statin use and cancer as well as in the association between the rapid decrease of blood pressure following antihypertensive treatment and cancerrelated mortality. Nevertheless, as Drs. Goldstein and Mascitelli state, this issue can be settled only by a prospective study of the effect of statins on cancer incidence and mortality.

show abstract

Rapid Decreases in Blood Pressure from Antihypertensive Treatment were Associated with Increased Cancer Mortality in the Systolic Hypertension in the Elderly Program

Cited by 5 publications

References 36 publications

Anais do Iº Congresso Internacional de Saúde Pública e Coletiva no SUS

Anais do Iº Congresso Internacional de Saúde Pública e Coletiva no SUS

Bevacizumab-Induced Hypertension in Glioblastoma Patients and Its Potential as a Modulator of Treatment Response

Cancer Death and Antihypertensive Drug Treatment—Response

Contact Info

Product

Resources

About